Olympus backs CMS coverage decision for lung cancer screening
CENTRAL VALLEY, Pennsylvania., May 24, 2022 /PRNewswire/ — Olympus, a world leader in the design and delivery of innovative medical technology solutions, has announced its support for the Centers for Medicare & Medicaid Services (CMS) decision to expand eligibility for breast cancer screening. lung to people covered by Medicare. The national coverage determination aligns with the recommendations of the US Preventive Services Task Force (USPSTF), lowering the age at which to start screening from 55 to 50 years and reducing the smoking history threshold by 30 packs- years to 20.i
This expanded eligibility is intended to improve health outcomes for patients with non-small cell lung cancer by allowing doctors to detect and diagnose lung cancer at an earlier stage. Symptoms of lung cancer usually only appear when the disease is already at an advanced stage, and detection in its later stages makes the prognosis grim. When detected early before the onset of symptoms, the disease is more likely to be treated and the patient’s chances of survival are greatly increased.ii The five-year survival rate for lung cancer is only 6 % for those diagnosed at a late stage after the switch to 60% for those diagnosed at an early stage before the tumor has spread.iii
“The extension of CMS coverage is a significant benefit for at-risk populations covered by Medicare. Earlier screening and detection can save the lives of people diagnosed with non-small cell lung cancer,” said Paul Skodny, executive director of Global Health Economics and Market. Access to Olympus Corporation of the Americas. “Yet much work remains to align CMS coverage through Medicare and Medicaid with lung cancer screening guidance so that barriers to screening are removed.”
The current national testing rate for people considered high risk is only 5.7%. electronic medical record to notify providers of patient eligibility for screening. This barrier is compounded by varying knowledge of screening guidelines among primary care providers.v
Screening for lung cancer with annual low-dose computed tomography (LDCT) is the standard of care for those at high risk, which includes current and former smokers. When implemented in accordance with recommendations from professional societies, lung cancer screening programs should include counseling patients on the screening process to determine eligibility and assist patients to participate in taking decisions about their care.vi
When patients are screened, most suspicious tumors are seen in the hard-to-reach outer third of the lungs, known as the peripheral lung. tumor to be cancerous. With this critical pathological information, physicians can offer patients the best treatment options and the most favorable prognosis.viii,ix,x
Through its product portfolio, Olympus is committed to improving the care pathway for lung cancer patients. The company’s minimally invasive technologies aim to advance the standard of care for the detection and diagnosis of this deadly disease. The SPiN Thoracic Navigation System™ and Radial EBUS (Endobronchial Ultrasound) procedures are designed to locate and harvest peripheral lung nodules. The EBUS-TBNA (endobronchial ultrasound-transbronchial needle aspiration) procedure uses a bronchoscope equipped with ultrasound capability designed to visualize the lymph nodes beyond the bronchus and determine their exact location for needle aspiration. ‘needle. The 2013 CHEST guidelines recommend EBUS-TBNA over surgical staging (mediastinoscopy) as the best first procedure.xi
About OlympusOlympus uses innovative capabilities in medical technology, therapeutic intervention and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic and minimally invasive procedures to improve clinical outcomes, reduce overall costs and improve the quality of life of patients. Olympus’ medical portfolio includes endoscopes, laparoscopes and video imaging systems, as well as surgical energy devices, system integration solutions, medical services and a wide range of endotherapy instruments. For more information, visit medical.olympusamerica.com.
i Final Recommendation Statement Lung Cancer: Screening. US Task Force on Preventive Services. Published March 9, 2021. Accessed May 20, 2022. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screeningii https://www.cancer.org/cancer/lung-cancer/detection-diagnosis -staging/detection.html#referencesiii National Cancer Institute. Monitoring Research Program, SEER*Explorer interactive website. https://seer.cancer.gov/explorer/iv https://www.lung.org/research/state-of-lung-cancer/key-findings American Lung Association, State of the Lung Cancer 2020 Report, accessed in August 2021v Coughlin JM, Zang Y, Terranella S, et al. Understanding barriers to lung cancer screening in primary care. J Thorac Dis. 2020;12(5):2536-2544. doi:10.21037/jtd.2020.03.66vi Mazzone PJ, Silvestri GA, Souter LH, Caverly TJ, Kanne JP, Katki HA, Wiener RS, Detterbeck FC. Executive summary: Lung cancer screening: chest guidelines and expert panel report. Chest. 2021 Nov;160(5):1959-1980. doi:10.1016/j.chest.2021.07.003. Epub 13 Jul 2021. PMID: 34270965; PMCID: PMC8727851.vii Horeweg N, van der Aalst CM, Thunnissen E, Nackaerts K, Weenink C, Groen HJ, Lammers JW, Aerts JG, Scholten ET, van Rosmalen J, Mali W, Oudkerk M, de Koning HJ. Characteristics of lung cancers detected by computed tomography screening in the NELSON randomized trial. Am J Respir Crit Care Med. 2013 Apr 15;187(8):848-54. doi: 10.1164/rccm.201209-1651OC. PMID: 23348977.viii Steinfort DP, Siva S, Leong TL, Rose M, Herath D, Antippa P, et al. Systematic endobronchial ultrasound-guided mediastinal staging versus positron emission tomography for complete mediastinal staging in NSCLC before radical radiation therapy for non-small cell lung cancer: a pilot study. Medicine (Baltimore) 2016;95:e2488. doi:10.1097/md.0000000000002488ix Guarize J, Casiraghi M, Donghi S, Casadio C, Diotti C, Filippi N, et al. EBUS-TBNA in PET-positive lymphadenopathy in treated cancer patients. ERJ Open Res 2017;3. doi:10.1183/23120541.00009-2017.x Jantz M A. Lung cancer staging: accuracy is key. J Chest disease 2019: S1322-S1324. doi: 10.21037/jtd.2019.04.18xi Silvestri GA, Gonzalez AV, Jantz MA, Margolis ML, Gould MK, Tanoue LT, et al. Staging methods for non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed. : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2013;143:e211S-e250S. doi:10.1378/chest.12-2355.
View original content for multimedia download: https://www.prnewswire.com/news-releases/olympus-supports-cms-coverage-decision-for-lung-cancer-screening-301554104.html